Gut Microbiome Affects the Response to Anti-Pd-1 Immunotherapy in Patients With Hepatocellular Carcinoma

Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1186/s40425-019-0650-9
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

CTLA4 Methylation Predicts Response to Anti–PD-1 and Anti–CTLA-4 Immunotherapy in Melanoma Patients

JCI insight
Medicine
2018English

Circulating Tumour DNA for Monitoring Treatment Response to Anti-Pd-1 Immunotherapy in Melanoma Patients

Acta Dermato-Venereologica
DermatologyMedicine
2017English

Impact of Glucocorticoids on the Gut Microbiome With or Without Anti-Pd-L1

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2019English

Immunotherapy of Hepatocellular Carcinoma With Magnetic PD-1 Peptide-Imprinted Polymer Nanocomposite and Natural Killer Cells

Biomolecules
BiochemistryMolecular Biology
2019English

Intestinal Microbiota Predict Response and Toxicities During Anti-Pd-1/Anti-Ctla-4 Immunotherapy

Pathology
Forensic MedicinePathology
2020English

820 M6A mRNA Demethylase FTO Regulates Tumorigenicity and Response to Anti-Pd-1 Immunotherapy in Melanoma

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Dynamic Metrics-Based Biomarkers to Predict Responders to Anti-Pd-1 Immunotherapy

British Journal of Cancer
Cancer ResearchOncology
2018English

Pulmonary Arterial Hypertension Affects the Rat Gut Microbiome

Scientific Reports
Multidisciplinary
2018English

Upregulation of Circulating PD-L1/PD-1 Is Associated With Poor Post-Cryoablation Prognosis in Patients With HBV-Related Hepatocellular Carcinoma

PLoS ONE
Multidisciplinary
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy